Anzeige
Mehr »
Login
Samstag, 10.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Super Gelegenheit! 4.000%-Kandidat mit letzter Gelegenheit vor dem Big Bang!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 753718 ISIN: US98956P1021 Ticker-Symbol: ZIM 
Tradegate
09.04.21
16:30 Uhr
139,70 Euro
+1,50
+1,09 %
Branche
Gesundheitswesen
Aktienmarkt
S&P 500
1-Jahres-Chart
ZIMMER BIOMET HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ZIMMER BIOMET HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
138,05140,7512:35
142,05142,7509.04.
PR Newswire
292 Leser
Artikel bewerten:
(1)

Bactiguard-coated Zimmer Biomet trauma implants receive European regulatory clearance

STOCKHOLM, Jan. 21, 2021 /PRNewswire/ -- Today, Bactiguard-coated Zimmer Biomet orthopaedic trauma implants received European regulatory clearance and CE mark. Preparations for registering the implants in the U.S. market are also ongoing.

"I am very pleased that the CE mark has been secured for Bactiguard-coated Zimmer Biomet trauma implants. This clearance will pave the way for European market launch in 2021. At the same time, we are preparing for the submission of the U.S regulatory file," says Cecilia Edström, Bactiguard CEO.

The partnership with Zimmer Biomet has the potential to expand Bactiguard's current license business and make a substantial contribution to its recurring license revenues.

Background to Bactiguard's license agreement with Zimmer Biomet

In 2015, a partnership was initiated between Bactiguard and Vigilenz Medical Devices for Bactiguard coated orthopaedic trauma implants, covering the ASEAN region in South East Asia. The implants were CE marked in December 2018 and have been used as a reference in the process of obtaining regulatory clearance for Zimmer Biomet's trauma implants. Vigilenz Medical Devices was acquired by Bactiguard in 2020 and is now a wholly-owned subsidiary.

In September 2019, Bactiguard entered an exclusive, global license agreement for orthopaedic trauma implants with Zimmer Biomet. The agreement included an upfront license fee of USD 3 million, additional contingent payments of USD 2 million based on U.S. regulatory clearance and royalties on net sales following commercialization.

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2021-01-21, at. 18.30.

For further information, please contact:
Cecilia Edström, CEO, phone: +46 72 226 23 28

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bactiguard-holding-ab--publ-/r/bactiguard-coated-zimmer-biomet-trauma-implants-receive-european-regulatory-clearance,c3272121

The following files are available for download:

https://mb.cision.com/Main/9686/3272121/1362133.pdf

210121 Bactiguard-coated Zimmer Biomet trauma implants receive European regulatory clearance

https://news.cision.com/bactiguard-holding-ab--publ-/i/trauma-implant,c2869815

Trauma implant

ZIMMER BIOMET-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.